Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines has said that NGX426, an oral therapy for the treatment of acute migraine and chronic pain conditions was well tolerated in a phase I trial.
Subscribe to our email newsletter
The compound is an oral prodrug of the company’s lead compound, tezampanel.
This phase I study was designed to evaluate the safety, tolerability and pharmacokinetics of NGX426, as well as to determine the rate and extent of conversion of the prodrug, NGX426, to the active drug tezampanel. Tezampanel is currently in a phase IIb clinical trial for acute migraine.
NGX426 was found to be well tolerated and rapidly converted to tezampanel at all doses tested. If successful, an oral version of tezampanel would diversify TorreyPines pipeline and has the potential to provide more commercialization opportunities for the company. Reported adverse events were generally mild in intensity and similar to those previously reported for tezampanel.
NGX426 and tezampanel offer a unique mechanism of analgesia that is non-narcotic and non-vascular in approach. As such, both compounds may effectively relieve pain without imparting the risks and side effects associated with currently available treatments. These compounds may offer an effective alternative for migraine sufferers for whom the current treatment is contraindicated.